Analyst consensus rating
GRI Bio Analyst Rating: none
Direct answer
GRI Bio's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $18.50.
Forecast evidence checked November 17, 2026.
Get free GRI Bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.40
- Average price target
- $18.50
- High price target
- $27.00
- Low price target
- $10.00
- Low target gap
- +614.3%
- Target upside
- +1,221.4%
- High target gap
- +1,828.6%
- Target range width
- 1,214.3%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- November 17, 2026
- Valid through
- November 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for GRI Bio?
GRI Bio has a verified none consensus. The same dataset has an average price target of $18.50.
How far are GRI Bio's low and high targets from the recorded price?
The low target implies +614.3%, while the high target implies +1,828.6%.
How many analysts are included in GRI Bio's consensus?
The verified consensus includes 2 analysts.
How is GRI Bio's target upside or downside calculated?
The average target of $18.50 is divided by the recorded price of $1.40, then one is subtracted to produce +1,221.4%. This does not guarantee a future return.
When was GRI Bio's analyst forecast verified?
The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.